Articles Vol. 67 No. Số CĐ12- Bệnh viện Ung bướu Nghệ An (2026) 14/08/2026

EVALUATION OF ADJUVANT RADIOTHERAPY OUTCOMES IN STAGE I–III BREAST CANCER AT NGHE AN ONCOLOGY HOSPITAL

Tran Xuan Yen1,2, Nguyen Kim Thanh1,2, Phan Xuan Tham1,2, Nguyen Hoang Tan1,2
1 Nghe An Oncology Hospital.
2 Bệnh viện Ung bướu Nghệ An.
DOI: 10.52163/yhc.v67iCD12.6145
625 Views
0 Downloads
Keywords
Breast cancer; adjuvant radiotherapy; locoregional recurrence; disease-free survival; overall survival.
Abstract

Objective: To evaluate the clinical outcomes of adjuvant radiotherapy in patients with stage I–III breast cancer treated at Nghe An Oncology Hospital.

Methods: This retrospective longitudinal descriptive study included 91 patients with stage I–III breast cancer who received adjuvant radiotherapy at Nghe An Oncology Hospital between January and December 2020. Clinical characteristics, treatment outcomes, survival, treatment-related toxicities, and prognostic factors were analyzed.

Results: The mean age of the study population was 51.66 ± 11.41 years. Stage I, II, and III disease accounted for 3.3%, 69.2%, and 27.5% of patients, respectively. The rates of locoregional recurrence, distant metastasis, and absence of recurrence or metastasis were 4.4%, 15.4%, and 80.2%, respectively. The 3-year locoregional recurrence-free survival (LRRFS), disease-free survival (DFS), and overall survival (OS) rates were 96.4%, 77.8%, and 84.5%, respectively, while the corresponding 5-year rates were 95.0%, 70.1%, and 74.5%. Late radiation-related toxicities were infrequent and predominantly mild, with lymphedema occurring in 5.49%, radiation-induced pulmonary fibrosis in 12.08%, and chest wall fibrosis in 2.19% of patients. Disease stage was an independent prognostic factor for disease-free survival (HR = 0.36, 95% CI: 0.13–0.98; p = 0.046)..

Conclusions: Adjuvant radiotherapy is an effective and safe treatment modality for patients with stage I–III breast cancer, providing excellent locoregional control with a low incidence of treatment-related toxicities. Disease stage was an independent prognostic factor for disease-free survival.

References
[1]
Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2024;74(3):229-263. doi:10.3322/caac.21834 Google Scholar
[2]
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Darby S, McGale P, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378(9804):1707-1716. doi:10.1016/S0140-6736(11)61629-2 Google Scholar
[3]
EBCTCG (Early Breast Cancer Trialists’ Collaborative Group), McGale P, Taylor C, et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014;383(9935):2127-2135. doi:10.1016/S0140-6736(14)60488-8 Google Scholar
[4]
Park KH, Loibl S, Sohn J, et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with early breast cancer. ESMO Open. 2024;9(5):102974. doi:10.1016/j.esmoop.2024.102974 Google Scholar
[5]
Anders CK, Johnson R, Litton J, Phillips M, Bleyer A. Breast cancer before age 40 years. Semin Oncol. 2009;36(3):237-249. doi:10.1053/j.seminoncol.2009.03.001 Google Scholar
[6]
Chitapanarux I, Klunklin P, Pinitpatcharalert A, et al. Conventional versus hypofractionated postmastectomy radiotherapy: a report on long-term outcomes and late toxicity. Radiat Oncol. 2019;14:175. doi:10.1186/s13014-019-1378-x Google Scholar
[7]
Kheradmand AA, Ranjbarnovin N, Khazaeipour Z. Postmastectomy locoregional recurrence and recurrence-free survival in breast cancer patients. World J Surg Onc. 2010;8(1):30. doi:10.1186/1477-7819-8-30 Google Scholar
[8]
Zhang Y, Zhang Y, Liu Z, et al. Impact of Postmastectomy Radiotherapy on Locoregional Control and Disease-Free Survival in Patients with Breast Cancer Treated with Neoadjuvant Chemotherapy. J Oncol. 2021;2021:6632635. doi:10.1155/2021/6632635 Google Scholar
[9]
Lin Y, Xu Y, Wang C, et al. Loco-regional therapy and the risk of breast cancer-related lymphedema: a systematic review and meta-analysis. Breast Cancer. 2021;28(6):1261-1272. doi:10.1007/s12282-021-01263-8 Google Scholar
[10]
Koo TR, Eom KY, Kang EY, et al. Prognostic value of the nodal ratio and ki-67 expression in breast cancer patients treated with postmastectomy radiotherapy. J Breast Cancer. 2013;16(3):274-284. doi:10.4048/jbc.2013.16.3.274 Google Scholar